Drugs / KZR-261
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05047536 | Sep 2021 → Jan 2025 | — | Kezar Life Sciences, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KZR-261 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05047536 ↗ |
| Action | Inhibit | “Sec61 Inhibitor” NCT05047536 ↗ |
| Modality | Small molecule | “a Small Molecule Sec61 Inhibitor” NCT05047536 ↗ |
| Route | Intravenous | “intravenous (IV) infusion” NCT05047536 ↗ |